MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy

Drug Resistant Epilepsy Clinical Trial

Official title:

Role of Plasma miRNA223 and High Mobility Group Box 1(HMGB1) as Predictors of Drug Resistant Epilepsy

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05555537
• Other study ID #: drug resistant epilepsy
• Status: Not yet recruiting
• Start date: November 1, 2022
• Est. completion date: November 1, 2024

Study information

• Verified date: October 2022
• Source: Assiut University
• Contact: Safaa Ali Ali, Assistant lecture
• Phone: 01018612254
• Email: safaa.samir191[@]gmail.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Evaluation of the role of estimation of serum level of miRNAs223 and HMGB1in detection of patient with drug resistant epilepsy.

Early detection of the prognosis might help in guiding patients for proper management and treatment strategy.

This may open the door for new drug trials.

Description:

Epilepsy is the most prevalent neurological disorders (1). Drug-resistant epilepsy (DRE) represent approximately 30% of epilepsy..DRE is defined as failure to achieve sustained seizure freedom after adequate and well tolerated trials of two antiseizure medications( ASMs).The identification of circulating biomarkers for DRE could give an early idea about the prognosis and improve the choice of correct treatment.

MiRNAs are small noncoding RNAs that span between 19 and 24 nucleotide bases((2).They gain biological activity through base pairing in the 30-untranslated regions of target messenger RNA (mRNA) , thereby guiding a protein complex termed the RNA-induced silencing complex (RISC) that bind to the mRNA sequence and results in either the inhibition of translational processes or the degradation of the mRNA (3). Dysregulated miRNA expression has been associated with inflammatory pathways, cell death, neuronal excitability, and synaptic reorganization, which underlie epileptogenesis (4).

High- mobility group box 1(HMGB1) is a chromatin component that is physiologically attached to nuclei. However, following CNS insult, it can promptly be migrated towards cytoplasm and is discharged extracellularly. HMGB1mediates sterile neuro-inflammation evoked by epileptogenic injury and recurrent seizures(5) .HMGB1 increases in neurons, glia, and endothelial cells of the blood brain barrier (BBB) in DRE.

The HMGB1 contributes to the overexpression of P-glycoprotein, a BBB protein, which is induced in DRE foci and extrudes various ASMs from the brain(6) .

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 90
• Est. completion date: November 1, 2024
• Est. primary completion date: October 1, 2024
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Patients diagnosed as drug resistant epilepsy .

• Control group: patients diagnosed as medically controlled epilepsy

Exclusion Criteria:

• Symptomatic epilepsy (vascular, tumor, post encephalitic, syndromic and febrile seizures).

• Alzheimers disease

• Parkinsons disease

• amyotrophic lateral sclerosis

• major depression disorder

• Non neurological criteria: tumors and cardiovascular

Related Conditions & MeSH terms

• Drug Resistant Epilepsy
• Epilepsy

Intervention

Diagnostic Test:
• MiRNA223 and High mobility group box1(HMGB1)
Measure tye 2 biomarkers miRNA223 and HMGB1 in drug resistant and in medically controled epilepsy

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Assiut University

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	role of estimation of serum level of miRNAs223 and HMGB1in detection of patient with drug resistant epilepsy.	Early detection of being drug resistant epilepsy might help in guiding patients for proper management and treatment strategy.	2year